Literature DB >> 16951210

Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression.

Aurora Costa1, Maria Grazia Daidone, Laura Daprai, Raffaella Villa, Sabrina Cantù, Silvana Pilotti, Luigi Mariani, Alessandro Gronchi, Jeremy D Henson, Roger R Reddel, Nadia Zaffaroni.   

Abstract

Human cancer cells maintain telomeres by telomerase activity (TA) or by alternative lengthening of telomeres (ALT). We proposed to define the prevalence of the two telomere maintenance mechanisms (TMM), to assess their association with histology, and to compare their prognostic relevance in a series of 93 patients with liposarcoma. ALT was detected by assaying ALT-associated promyelocytic leukemia nuclear bodies and TA was assayed using the telomeric repeat amplification protocol. ALT or TA was found in 25.9% or 26.6% of 139 tested liposarcoma lesions, respectively. Three lesions were ALT+/TA+ whereas approximately 50% of lesions did not show any known TMM. TMM phenotype was consistent during disease progression. ALT was prevalent in dedifferentiated and in grade 3 liposarcomas whereas TA prevailed in most round-cell myxoid and in grade 2 liposarcomas. ALT and TA incidence was similar in primary and recurrent lesions whereas metastases were more frequently TA+ than ALT+ (59% versus 18%; P = 0.04). TMM presence negatively affected patient prognosis (P = 0.001): increased mortality was associated with positivity for TA (P = 0.038) or ALT (P < 0.0001) compared with TMM absence. ALT proved to be a stronger prognostic discriminant of increased mortality than TA even when adjusted for tumor location, grade, and histology (hazard ratio for cause-specific death, 3.58 versus 1.15). Our results indicate that ALT can support fully malignant liposarcomas and is associated with unfavorable disease outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951210     DOI: 10.1158/0008-5472.CAN-06-0273

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.

Authors:  Kyle Lafferty-Whyte; Alan Bilsland; Stacey F Hoare; Sharon Burns; Nadia Zaffaroni; Claire J Cairney; William Nicol Keith
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

2.  Telomerase activity in pleural malignant mesotheliomas.

Authors:  Amy Y M Au; Torben Hackl; Thomas R Yeager; Scott B Cohen; Harvey I Pass; Curtis C Harris; Roger R Reddel
Journal:  Lung Cancer       Date:  2011-01-31       Impact factor: 5.705

3.  Detection of circular telomeric DNA without 2D gel electrophoresis.

Authors:  Margit Dlaska; Conrad Anderl; Wolfgang Eisterer; Oliver E Bechter
Journal:  DNA Cell Biol       Date:  2008-09       Impact factor: 3.311

4.  Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

Authors:  Christopher M Heaphy; Andrea P Subhawong; Seung-Mo Hong; Michael G Goggins; Elizabeth A Montgomery; Edward Gabrielson; George J Netto; Jonathan I Epstein; Tamara L Lotan; William H Westra; Ie-Ming Shih; Christine A Iacobuzio-Donahue; Anirban Maitra; Qing K Li; Charles G Eberhart; Janis M Taube; Dinesh Rakheja; Robert J Kurman; T C Wu; Richard B Roden; Pedram Argani; Angelo M De Marzo; Luigi Terracciano; Michael Torbenson; Alan K Meeker
Journal:  Am J Pathol       Date:  2011-09-01       Impact factor: 4.307

5.  Different expression of alternative lengthening of telomere (ALT)-associated proteins/mRNAs in osteosarcoma cell lines.

Authors:  Yi Zhang; Lin Cai; Ren-Xiong Wei; Hao Hu; Wei Jin; Xiao-Bin Zhu
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

Review 6.  Alternative lengthening of telomeres: models, mechanisms and implications.

Authors:  Anthony J Cesare; Roger R Reddel
Journal:  Nat Rev Genet       Date:  2010-03-30       Impact factor: 53.242

7.  Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.

Authors:  Jau-Yu Liau; Jen-Chieh Lee; Jia-Huei Tsai; Ching-Yao Yang; Tsung-Lin Liu; Zhi-Long Ke; Hung-Han Hsu; Yung-Ming Jeng
Journal:  Mod Pathol       Date:  2015-10-02       Impact factor: 7.842

8.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Authors:  Patrick J Killela; Zachary J Reitman; Yuchen Jiao; Chetan Bettegowda; Nishant Agrawal; Luis A Diaz; Allan H Friedman; Henry Friedman; Gary L Gallia; Beppino C Giovanella; Arthur P Grollman; Tong-Chuan He; Yiping He; Ralph H Hruban; George I Jallo; Nils Mandahl; Alan K Meeker; Fredrik Mertens; George J Netto; B Ahmed Rasheed; Gregory J Riggins; Thomas A Rosenquist; Mark Schiffman; Ie-Ming Shih; Dan Theodorescu; Michael S Torbenson; Victor E Velculescu; Tian-Li Wang; Nicolas Wentzensen; Laura D Wood; Ming Zhang; Roger E McLendon; Darell D Bigner; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Hai Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

9.  Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis.

Authors:  Lorenza Venturini; Rosita Motta; Alessandro Gronchi; MariaGrazia Daidone; Nadia Zaffaroni
Journal:  BMC Cancer       Date:  2010-06-03       Impact factor: 4.430

10.  A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT.

Authors:  K Lafferty-Whyte; C J Cairney; M B Will; N Serakinci; M-G Daidone; N Zaffaroni; A Bilsland; W N Keith
Journal:  Oncogene       Date:  2009-08-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.